IR Department
  • About Us
    • Overview
    • Our Team
    • Our ESG Position
    • Careers
  • Services
    • What We Do
    • Investor Relations
    • IPO Readiness
    • Media Relations
    • Issues and Crisis Communications
    • Digital Content & Social Media Activation
    • Marketing and Brand Campaigns
    • Video Production
    • ESG
    • ESG Competent Boards Masterclass
  • News & Events
    • Blog
  • Contact
    • Contact Us
    • Email Alerts

Recent Posts

  • HealthInvest June 2026: A Look Inside Australia's Healthcare Innovations16 Jun 2026
  • HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences19 May 2026
  • Lifesaving Capital: How impact investing is shaping the future of biotech30 Apr 2026
  • Investor Relations: the quiet advantage powering ASX microcaps28 Nov 2025
  • HealthInvest Sydney: Life Sciences in the Investor Spotlight06 Oct 2025

Archives

  • June 2026
  • May 2026
  • April 2026
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • April 2025
  • March 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • May 2024
  • December 2023
  • October 2023
  • July 2023
  • March 2023
  • February 2023

Categories

  • All
  • AGMs
  • Crisis Communications
  • Equity Insights
  • ESG
  • Investor Relations
  • Newsletter March 2022
  • Newsletter Sept 2022
  • Uncategorized

Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

29 Aug 2022·Newsletter Sept 2022
Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape in the near future.

 

Back to blog
ShareinX

IR Department acknowledge the Traditional Owners of the land on which it operates and pays respect to Elders past, present and emerging.

Subscribe


Site Map Privacy Search
IR Department . All rights reserved.